

careful consideration of anatomy can be rewarding in providing a likely explanation and path of treatment.

REFERENCE

1. Radhakrishnan D, Goyal V, Shukla G, Bhushan Singh M. Hemi masticatory spasm: series of 8 cases. *Neurology* 2019;**92**(15 Supplement):P4.8–052.

Poster Abstract

2576

12-MONTH EFFECTIVENESS AND TOLERABILITY OF BRIVARACETAM IN PATIENTS WITH EPILEPSY SWITCHING FROM LEVETIRACETAM VS OTHER ANTISEIZURE MEDICATIONS IN THE REAL-WORLD

¹Wendyl D'Souza*, ²Edward Faught, ³Pavel Klein, ⁴Markus Reuber, ⁵Felix Rosenow, ⁶Javier Salas-Puig, ⁷Victor Soto Insuga, ⁸Adam Strzelczyk, ⁹Bernhard J Steinhoff, ⁹Jerzy P Szaflarski, ¹⁰Herve Besson, ¹¹Dimitrios Bourikas, ¹²Tony Daniels, ¹³Florin Floricel, ¹⁴David Friesen, ¹⁵Cedric Laloyaux, ¹⁶Anita Moody, ¹⁵Veronica Sendersky, ¹⁷Vicente Villanueva. ¹The University of Melbourne, Melbourne, VIC, Australia; ²Emory Epilepsy Center, Atlanta, GA, USA; ³Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA; ⁴The University of Sheffield, Sheffield, UK; ⁵Epilepsy Center Frankfurt Rhine-Main, Frankfurt, Germany; ⁶Universitari Vall d'Hebron, Barcelona, Spain; ⁷Hospital Universitario Infantil Nino Jesus, Madrid, Spain; ⁸University of Freiburg, Freiburg, Germany; ⁹UAB Epilepsy Center, Birmingham, AL, USA; ¹⁰UCB Pharma, Breda, Netherlands; ¹¹UCB Pharma, Alimos, Greece; ¹²UCB Pharma, Morrisville, NC, USA; ¹³UCB Pharma, Monheim an Rhein, Germany; ¹⁴UCB Pharma, Slough, UK; ¹⁵UCB Pharma, Brussels, Belgium; ¹⁶UCB Pharma, Malvern, Australia; ¹⁷Hospital Universitario y Politecnico La Fe, Valencia, Spain

10.1136/bmjno-2023-ANZAN.37

Objectives Assess effectiveness and tolerability of brivaracetam (BRV) in patients switching from levetiracetam (LEV) and from other antiseizure medications (ASMs).

Method Subgroup analysis of EXPERIENCE/EPD332, a pooled analysis of patient-level data from patients with epilepsy initiating BRV in clinical practice. $\geq 50\%$ seizure reduction from baseline, seizure-freedom (SF; no seizures within 3 months prior to timepoint), continuous SF after baseline (CSF) and treatment-emergent adverse events (TEAEs) since prior visit were assessed at 12 months. Patients with missing data after BRV discontinuation were considered non-responders and not seizure-free.

Results 709 (43.8%) patients switched from LEV and 887 (54.8%) switched from other ASMs. Patients switching from LEV/other ASMs showed similar epilepsy duration (median: 18.0/17.0 years; $n=694/864$), seizure frequency at index (median: 4.0/4.3 seizures/28 days; $n=537/807$), number of prior ASMs (mean [SD]: 5.0 [3.7]/6.0 [3.9]; $n=709/887$) and incidence of psychiatric comorbidities at index (34.8%/39.7%; $n=704/866$). Most had focal-onset seizures at baseline (92.7%/91.9%). At index, median BRV dose was 100/50 mg/day in patients switching from LEV/other ASMs ($n=699/869$). Median BRV duration was 353.1/337.4 days ($n=703/878$). At 12 months, $\geq 50\%$ seizure reduction (34.6%/38.3% [$n=295/512$]), SF (14.9%/13.9% [$n=484/596$]), CSF (11.4%/10.9% [$n=484/596$]) and incidence of TEAEs (9.5%/9.1%; $n=525/662$) were similar in patients switching from LEV/other ASMs. Somnolence (3.0%/1.7%) was the most common TEAE. The incidence of irritability was 1.3%/0.5%, and aggression was 0.8%/0.3%. BRV discontinuations in patients switching from LEV/other ASMs were 32.0%/35.8%; $n=706/885$).

Conclusion Effectiveness and tolerability of BRV were similar in patients switching from LEV/other ASMs.

Funding/Disclosures: UCB Pharma-sponsored.

2578

REPETITIVE COMPOUND MUSCLE ACTION POTENTIAL: A DIAGNOSTIC CLUE IN CONGENITAL MYASTHENIC SYNDROMES

¹Shadi El-Wahsh, ¹Aicee Calma*, ¹Katrina Morris, ²Lisa Worgan, ¹Alastair Corbett, ¹James Triplett. ¹Neurology, Concord Repatriation General Hospital, Sydney, NSW, Australia; ²Clinical Genetics Service, Royal Prince Alfred Hospital, Sydney, NSW, Australia

10.1136/bmjno-2023-ANZAN.38

A 60-year-old man presented with fatigable limb-girdle weakness since the age of 4. Physical examination revealed fatigable proximal limb weakness with no ptosis, extraocular muscle weakness or bulbar dysfunction. Creatine kinase levels were normal and acetyl-choline receptor and MuSK receptor antibodies were negative. Nerve conduction studies revealed a repetitive compound muscle action potential (CMAP) following a single stimulus. Decrement was present on 3Hz repetitive nerve stimulation in proximal and distal limb muscles. Genetic analysis identified heterozygous variants in the COLQ gene, establishing a diagnosis of congenital myasthenic syndrome (CMS) due to endplate acetylcholinesterase deficiency. The patient improved with oral salbutamol therapy. A repetitive CMAP is a diagnostic clue for specific congenital myasthenic syndromes (CMS), namely COLQ deficiency and slow channel syndromes. A repetitive CMAP may also be seen in acetylcholinesterase inhibitor overuse and organophosphate poisoning. In the absence of toxicity, a repetitive CMAP in a patient with limb-girdle weakness should raise suspicion for CMS.

2581

VIVACITY MG PHASE 3 STUDY: CLINICAL TRIAL OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS

Sindhu SH Ramchandren*, Panna PS Sanga, Eriene EW Wasef, Hong HS Sun. *Research and Development, Janssen Research and Development, LLC, Titusville NJ, USA, Titusville, New Jersey, USA*

10.1136/bmjno-2023-ANZAN.39

Objectives Nipocalimab is a high affinity, fully human, aglycosylated, effectorless IgG1 anti FcRn monoclonal antibody that targets the neonatal Fc receptor (FcRn) with high affinity, thereby lowering IgG pathogenic antibodies in autoimmune disease. Data from Vivacity-MG, a Phase 2 randomized placebo-controlled study of nipocalimab in adult generalized myasthenia gravis (gMG), demonstrated safety, tolerability, and efficacy of nipocalimab (clinicaltrials.gov NCT03772587). We describe Vivacity-MG3, our pivotal Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Nipocalimab Administered to Adults With gMG (NCT04951622).

Methods This global study will enroll approximately 180 participants with gMG, aged 18 and older, with an insufficient clinical response to ongoing, stable standard-of-care therapy, as reflected by a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of ≥ 6 at screening and baseline, and a Myasthenia Gravis Foundation of America (MGFA) Class of IIa/b – IVa/b at screening. The study will consist of a screening period of up to 4 weeks, a 24-week double-blind placebo-controlled phase where participants will be randomly assigned in a 1:1 ratio to receive either placebo or nipocalimab